Kernstatistik
Eurostat put EU healthcare expenditure at 10.0% of GDP in 2023, while pharmaceutical sold production reached EUR 263 billion in 2024 - so demand is there, but the constraint is execution under regulation.
Warum es wichtig ist
Life sciences is one of the few European sectors where demand, innovation and regulation all intensified at once. That creates opportunity, but only for teams that can handle data interoperability, patient and HCP access, regulatory evidence and increasingly AI-enabled workflows under strong governance. EUR 263bn 2024 sold production in pharmaceutical products EUR 55bn R&D; invested by Europe's research-based pharma industry in 2024 10.0% EU healthcare expenditure as a share of GDP in 2023
Executive Summary
The sector is expanding, but execution is constrained by regulation, fragmented data and health-system capacity. The winners in 2025-2026 will be those that simplify evidence generation, modernise regulatory and clinical operations, and improve access, engagement and service without losing compliance discipline. In healthcare delivery, the immediate question is workforce and capacity. In biotech and pharma, the question is how to use data and AI responsibly to accelerate development, market access and operational resilience. Europe is digitising, but health and life-science use cases demand stronger governance than most sectors. AI and data programs need documented controls, interoperability and explicit legal review much earlier than typical enterprise automation projects.
Premium-Bereich
Das vollständige Pack ergänzt Action Agenda, Regulation Watch, Provider-Landscape und tiefere operative Guidance hinter diesem Teaser.
Für wen sich das lohnt
- Life-sciences, healthcare, and biotech teams working under evidence, access, and regulatory constraints.
- Commercial and medical leaders responsible for governed engagement and market access quality.
- Data and operations teams modernising regulatory, clinical, or care workflows.
Drei nächste Fragen
- Which evidence, documentation, or approval workflow creates the most friction today?
- Where could one governed AI or automation use case remove administrative load without increasing risk?
- How reusable and interoperable are the data assets behind clinical, regulatory, and commercial decisions?